Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Average Recommendation of "Buy" by Analysts

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) has been assigned a consensus recommendation of "Buy" from the nine brokerages that are presently covering the stock, Marketbeat.com reports. Eight research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $53.50.

A number of equities analysts have recently issued reports on the company. BTIG Research set a $48.00 target price on Arcturus Therapeutics and gave the stock a "buy" rating in a research note on Monday, March 10th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Arcturus Therapeutics in a research report on Friday, March 7th. Wall Street Zen raised Arcturus Therapeutics from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Scotiabank assumed coverage on shares of Arcturus Therapeutics in a research note on Wednesday, May 28th. They set a "sector outperform" rating and a $32.00 price target on the stock. Finally, HC Wainwright reiterated a "buy" rating and issued a $60.00 price target on shares of Arcturus Therapeutics in a report on Thursday, April 10th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in ARCT. Charles Schwab Investment Management Inc. increased its holdings in Arcturus Therapeutics by 5.2% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 207,802 shares of the biotechnology company's stock valued at $3,526,000 after acquiring an additional 10,180 shares in the last quarter. Tocqueville Asset Management L.P. increased its stake in shares of Arcturus Therapeutics by 42.7% during the 4th quarter. Tocqueville Asset Management L.P. now owns 22,400 shares of the biotechnology company's stock worth $380,000 after purchasing an additional 6,700 shares in the last quarter. American Century Companies Inc. increased its stake in shares of Arcturus Therapeutics by 10.7% during the 4th quarter. American Century Companies Inc. now owns 47,018 shares of the biotechnology company's stock worth $798,000 after purchasing an additional 4,547 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new position in shares of Arcturus Therapeutics during the 4th quarter worth approximately $71,000. Finally, Vanguard Group Inc. lifted its stake in Arcturus Therapeutics by 6.8% in the 4th quarter. Vanguard Group Inc. now owns 1,684,561 shares of the biotechnology company's stock valued at $28,587,000 after buying an additional 107,635 shares in the last quarter. Institutional investors and hedge funds own 94.54% of the company's stock.

Arcturus Therapeutics Stock Performance

NASDAQ:ARCT opened at $12.28 on Wednesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 5.64 and a quick ratio of 5.64. The firm has a market cap of $333.03 million, a price-to-earnings ratio of -4.85 and a beta of 2.30. The firm's fifty day moving average price is $11.89 and its 200 day moving average price is $14.36. Arcturus Therapeutics has a 1-year low of $8.04 and a 1-year high of $28.17.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last issued its earnings results on Monday, May 12th. The biotechnology company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($1.58) by $1.06. The business had revenue of $29.38 million for the quarter, compared to the consensus estimate of $25.64 million. Arcturus Therapeutics had a negative net margin of 47.47% and a negative return on equity of 27.41%. On average, sell-side analysts expect that Arcturus Therapeutics will post -2.22 EPS for the current year.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.